Literature DB >> 20334489

Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.

Thomas H Beckham1, Saeed Elojeimy, Joseph C Cheng, Lorianne S Turner, Stanley R Hoffman, James S Norris, Xiang Liu.   

Abstract

IMPORTANCE OF THE FIELD: Ceramide accumulation has been shown to be a conserved mechanism of apoptosis initiation in normal physiological processes as well as in response to cancer treatments. Therefore, it is unsurprising that many cancers develop aberrations of sphingolipid metabolism that prevent the accumulation of ceramide, whether by reduction of ceramide generation or by enhanced ceramide catabolism, particularly dangerous when catabolism leads to generation of pro-tumor sphingosine-1-phosphate and ceramide-1-phosphate. Numerous studies have now implicated dysregulation of sphingolipid metabolism in head and neck cancers. AREAS COVERED IN THIS REVIEW: This review highlights the importance of sphingolipid metabolism and brings sphingolipid metabolism to the forefront in the investigation of novel therapies for head and neck cancer. It reviews sphingolipid-centric therapies under investigation in preclinical and clinical trials of cancers of the head and neck. WHAT THE READER WILL GAIN: The roles of sphingolipids and sphingolipid metabolism in cancer are reviewed and the reader will be brought up to date with discoveries in the field of sphingolipid metabolism in head and neck cancer. TAKE HOME MESSAGE: As treatments for head and neck cancers are currently limited, the potential of targeting sphingolipid metabolism should be taken into consideration as we seek novel ways to combat this group of tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20334489      PMCID: PMC2861896          DOI: 10.1517/14728221003752768

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  95 in total

Review 1.  The therapeutic potential of modulating the ceramide/sphingomyelin pathway.

Authors:  Richard Kolesnick
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1.

Authors:  Charles E Chalfant; Kristin Rathman; Ryan L Pinkerman; Rachel E Wood; Lina M Obeid; Besim Ogretmen; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2002-01-18       Impact factor: 5.157

3.  Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models.

Authors:  Haruhito Azuma; Shiro Takahara; Naotsugu Ichimaru; Jing Ding Wang; Yuko Itoh; Yoshinori Otsuki; Junji Morimoto; Ryosuke Fukui; Masaaki Hoshiga; Tadashi Ishihara; Norio Nonomura; Seiichi Suzuki; Akihiko Okuyama; Yoji Katsuoka
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

4.  FAS activation induces dephosphorylation of SR proteins; dependence on the de novo generation of ceramide and activation of protein phosphatase 1.

Authors:  C E Chalfant; B Ogretmen; S Galadari; B J Kroesen; B J Pettus; Y A Hannun
Journal:  J Biol Chem       Date:  2001-08-13       Impact factor: 5.157

5.  Importance of C1B domain for lipid messenger-induced targeting of protein kinase C.

Authors:  Kaori Kashiwagi; Yasuhito Shirai; Masamitsu Kuriyama; Norio Sakai; Naoaki Saito
Journal:  J Biol Chem       Date:  2002-03-04       Impact factor: 5.157

Review 6.  Designing anticancer drugs via the achilles heel: ceramide, allylic ketones, and mitochondria.

Authors:  Norman S Radin
Journal:  Bioorg Med Chem       Date:  2003-05-15       Impact factor: 3.641

7.  Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro.

Authors:  Jennifer A Shabbits; Lawrence D Mayer
Journal:  Biochim Biophys Acta       Date:  2003-05-02

8.  Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy.

Authors:  David A Litvak; Anton J Bilchik; Myles C Cabot
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

Review 9.  Oral cancer treatment.

Authors:  Terry A Day; Betsy K Davis; M Boyd Gillespie; John K Joe; Megan Kibbey; Bonnie Martin-Harris; Brad Neville; Mary S Richardson; Steven Rosenzweig; Anand K Sharma; Michelle M Smith; Stacy Stewart; Robert K Stuart
Journal:  Curr Treat Options Oncol       Date:  2003-02

10.  Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase.

Authors:  Michael Weiss; Simone Hettmer; Paul Smith; Stephan Ladisch
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

View more
  10 in total

1.  Induction of apoptosis in prostate cancer cells by the novel ceramidase inhibitor ceranib-2.

Authors:  Gokhan Kus; Selda Kabadere; Ruhi Uyar; Hatice Mehtap Kutlu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-07-14       Impact factor: 2.416

Review 2.  Development of small-molecule inhibitors of sphingosine-1-phosphate signaling.

Authors:  Yvette Edmonds; Sheldon Milstien; Sarah Spiegel
Journal:  Pharmacol Ther       Date:  2011-08-27       Impact factor: 12.310

Review 3.  Many ceramides.

Authors:  Yusuf A Hannun; Lina M Obeid
Journal:  J Biol Chem       Date:  2011-06-21       Impact factor: 5.157

4.  Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.

Authors:  Samy A F Morad; Jonathan C Levin; Sriram S Shanmugavelandy; Mark Kester; Gemma Fabrias; Carmen Bedia; Myles C Cabot
Journal:  Mol Cancer Ther       Date:  2012-09-07       Impact factor: 6.261

5.  LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria.

Authors:  Thomas H Beckham; Ping Lu; Elizabeth E Jones; Tucker Marrison; Clayton S Lewis; Joseph C Cheng; Venkat K Ramshesh; Gyda Beeson; Craig C Beeson; Richard R Drake; Alicja Bielawska; Jacek Bielawski; Zdzislaw M Szulc; Besim Ogretmen; James S Norris; Xiang Liu
Journal:  J Pharmacol Exp Ther       Date:  2012-10-18       Impact factor: 4.030

6.  Ceramide in cystic fibrosis: a potential new target for therapeutic intervention.

Authors:  Gabriella Wojewodka; Juan B De Sanctis; Danuta Radzioch
Journal:  J Lipids       Date:  2010-12-28

7.  C2-ceramide induces cell death and protective autophagy in head and neck squamous cell carcinoma cells.

Authors:  Wenyuan Zhu; Xinhua Wang; Yi Zhou; Huiming Wang
Journal:  Int J Mol Sci       Date:  2014-02-21       Impact factor: 5.923

Review 8.  Inhibitors of Ceramide- and Sphingosine-Metabolizing Enzymes as Sensitizers in Radiotherapy and Chemotherapy for Head and Neck Squamous Cell Carcinoma.

Authors:  Yoshiaki Yura; Atsushi Masui; Masakazu Hamada
Journal:  Cancers (Basel)       Date:  2020-07-26       Impact factor: 6.639

9.  Bioactive sphingolipid profile in a xenograft mouse model of head and neck squamous cell carcinoma.

Authors:  Aiping Bai; Xiang Liu; Jacek Bielawski; Yusuf A Hannun
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

10.  The impact of sphingosine kinase-1 in head and neck cancer.

Authors:  Paulette M Tamashiro; Hideki Furuya; Yoshiko Shimizu; Kayoko Iino; Toshihiko Kawamori
Journal:  Biomolecules       Date:  2013-08-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.